EMBARC - Engineering modulators of brown adipose receptors

Value proposition
We are developing compounds that stimulate the calorie-burning and blood sugar-lowering actions of a unique organ called brown adipose tissue.

Business Opportunity
The obesity drug market is expected to hit 53 billion DKK by 2021. Moreover, all current obesity drugs on the market operate by reducing food intake, whereas our drug candidate increases calorie-burning. Consequently, we believe our candidate has a chance to establish a significant market share as a stand-alone or an add-on therapy to current options.

Technology description
The technology is used to treat obesity and diabetes by activating brown adipose tissue. By targeting specific receptors that trigger the glucose consuming and fat burning functions of brown adipose tissue we hope to decrease blood sugar and adiposity.

Development phase
We are currently strengthening the proof-of-concept experiments and developing lead compounds.

The inventors
Associate Professor Zachary Gerhart-Hines (UCPH)
Postdoctoral Fellow Jakob Bondo Hansen (UCPH)
Professor Thue W. Schwartz (UCPH)

Contact information
Peter Stein Nielsen
Commercial Officer
Peter.nielsen@adm.ku.dk
+45 2164 7447

Intellectual property rights: Danish priority application filed on December 22, 2016